{"filings":[{"id":1977676,"accession_number":"0001104659-26-089008","cik":1821825,"company_name":"Organon & Co.","ticker":"OGN","form_type":"8-K","filed_at":"2026-07-31T12:23:43+00:00","items":["7.01","9.01"],"status":"ready","headline":"Organon furnishes supplemental non-GAAP Q2 2026 metrics; merger with Sun Pharma pending","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company released Q2 2026 financial results via Form 10-Q, not a press release, due to pending merger with Sun Pharmaceutical Industries.","Supplemental non-GAAP metrics for Q2 2026 are furnished in Exhibit 99.1 but no specific figures are provided in the filing text.","Customary earnings press release and conference call suspended for the quarter.","Non-GAAP measures are intended to supplement GAAP results; full GAAP disclosures are in the 10-Q filed July 31, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3508347527.7428994,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1831876,"accession_number":"0001193125-26-314587","cik":1821825,"company_name":"Organon & Co.","ticker":"OGN","form_type":"8-K","filed_at":"2026-07-23T21:13:19+00:00","items":["5.07"],"status":"ready","headline":"Organon shareholders approve merger with Sun Pharma; 98.7% of votes cast in favor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Proposal to adopt merger agreement passed with 192,776,552 votes for, 2,573,118 against, 326,189 abstaining.","Advisory vote on merger-related executive compensation approved: 185,141,986 for, 9,553,830 against, 980,043 abstaining.","74.51% of outstanding shares (195,675,859) were represented at the July 23, 2026 special meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":3508347527.7428994,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1718676,"accession_number":"0001193125-26-307767","cik":1821825,"company_name":"Organon & Co.","ticker":"OGN","form_type":"8-K","filed_at":"2026-07-17T20:01:17+00:00","items":["8.01"],"status":"ready","headline":"Organon supplements proxy with $700M synergy estimate; shareholder lawsuit seeks to delay merger vote","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Shareholder lawsuit filed July 6 in NJ Superior Court alleges proxy disclosures are materially incomplete and misleading.","Company voluntarily supplements proxy with preliminary cost synergy estimate of ~$700M from Sun Pharma transaction.","Provides financial projections: 2026E revenue $6,252M, Adj EBITDA $1,894M, unlevered FCF $1,010M.","Net debt $7,530M, fully diluted shares ~284.9M as of April 24, 2026; LTM Adj EBITDA $1,832M.","Special meeting of stockholders to vote on merger remains scheduled for July 23, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3508347527.7428994,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1000359,"accession_number":"0001104659-26-072953","cik":1821825,"company_name":"Organon & Co.","ticker":"OGN","form_type":"8-K","filed_at":"2026-06-11T20:15:47+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Organon stockholders approve 8M share increase to 2021 incentive plan at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amended 2021 Incentive Stock Plan approved by 142.5M for, 7.6M against, 1.8M abstain; 50.8M broker non-votes.","Plan increases authorized common shares available for issuance by 8,000,000 shares.","All ten director nominees elected, each receiving >143M votes for; say-on-pay and auditor ratification also approved.","Broker non-votes of 50.8M shares occurred on all proposals except auditor ratification.","Meeting held June 9, 2026; 202.6M shares represented (~77% of outstanding)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":3508347527.7428994,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95830,"accession_number":"0001104659-26-052165","cik":1821825,"company_name":"Organon & Co.","ticker":"OGN","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Organon Q1 revenue $1.46B (-4% YoY); declares $0.02 dividend; Sun Pharma merger pending","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1.460B, down 4% as-reported, down 9% ex-FX; Women's Health -16%, Biosimilars +23%.","GAAP diluted EPS $0.55, Adjusted diluted EPS $0.71; Adjusted EBITDA $415M (28.4% margin).","Board declares quarterly dividend of $0.02/share, payable June 11 to holders of record May 11.","Pending all-cash merger with Sun Pharma expected to close early 2027; guidance and earnings calls suspended.","Net income $146M vs $87M YoY; cash and equivalents $1.12B, debt $8.57B."],"consensus_eps_estimate":null,"consensus_eps_actual":0.55,"consensus_revenue_estimate":null,"consensus_revenue_actual":1460000000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":3508347527.7428994,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95829,"accession_number":"0001193125-26-178718","cik":1821825,"company_name":"Organon & Co.","ticker":"OGN","form_type":"8-K","filed_at":"2026-04-27T23:59:59+00:00","items":["1.01","5.02","7.01","9.01"],"status":"ready","headline":"Sun Pharma to acquire Organon for $14.00/share in all-cash deal; EV $11.75B","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquisition price $14.00/share in cash, a 103% premium to Organon's closing price on April 9, 2026.","Enterprise value of $11.75B; combined revenue of $12.4B (Sun Pharma FY24-25 and Organon CY2025).","Transaction approved by both boards; subject to Organon stockholder vote and regulatory approvals.","Joseph Morrissey appointed permanent CEO of Organon; Carrie Cox appointed permanent Executive Chair.","Sun Pharma secured committed financing; pro forma Net Debt/EBITDA of 2.3x expected."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":3508347527.7428994,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109160,"accession_number":"0001104659-26-017870","cik":1821825,"company_name":"Organon & Co.","ticker":"OGN","form_type":"8-K","filed_at":"2026-02-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Organon Audit Committee completes biosimilar purchase review, finds no improper conduct","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit Committee completed independent review of timing of biosimilar purchases from a supplier in prior years.","Review found no evidence of improper conduct and no adjustments to previously issued financial statements.","Company intends to file its Form 10-K for the year ended December 31, 2025 on time.","No changes required to SEC disclosures related to the transactions reviewed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":3508347527.7428994,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109159,"accession_number":"0001104659-26-013888","cik":1821825,"company_name":"Organon & Co.","ticker":"OGN","form_type":"8-K","filed_at":"2026-02-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Organon reports FY2025 rev $6.2B (-3%), GAAP EPS $0.72; guides FY2026 rev ~$6.2B, Adj EBITDA ~$1.9B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full year 2025 revenue $6.2B, down 3% YoY; GAAP diluted EPS $0.72, adjusted diluted EPS $3.66.","Q4 2025 revenue $1.507B (-5% as-reported, -8% ex-FX); Q4 GAAP net loss $205M vs income $109M prior year; adjusted diluted EPS $0.63 vs $0.90.","Women's Health Q4 revenue down 15%, Nexplanon down 20% ex-FX due to ceased U.S. wholesaler practices and policy access restrictions.","Biosimilars Q4 revenue up 11%, led by Hadlima and new assets (Bildyos, Bilprevda, Tofidence).","FY2026 guidance: revenue ~$6.2B, Adjusted EBITDA ~$1.9B, both in line with FY2025 performance."],"consensus_eps_estimate":null,"consensus_eps_actual":0.72,"consensus_revenue_estimate":null,"consensus_revenue_actual":6216000000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3508347527.7428994,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125657,"accession_number":"0001104659-25-108821","cik":1821825,"company_name":"Organon & Co.","ticker":"OGN","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Organon Q3 revenue $1.6B, adj. EPS $1.01; FY2025 guidance lowered","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $1.602B (+1% as-reported, -1% ex-FX); net income $160M vs $359M YoY (-55%).","GAAP diluted EPS $0.61; non-GAAP adjusted diluted EPS $1.01 (up 16% YoY).","Adjusted EBITDA $518M (32.3% margin), up from $459M (29.0%) YoY.","FY2025 revenue guidance cut to $6.200-6.250B; Adj EBITDA margin guidance ~31.0% (lowered).","Nexplanon sales down 9% ex-FX due to lower U.S. government funding; Biosimilars up 19% on Hadlima."],"consensus_eps_estimate":null,"consensus_eps_actual":1.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":4709000000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3508347527.7428994,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125656,"accession_number":"0001104659-25-108130","cik":1821825,"company_name":"Organon & Co.","ticker":"OGN","form_type":"8-K","filed_at":"2025-11-07T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Organon director Grace Puma will not stand for re-election at 2026 annual meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Grace Puma informed Organon on Nov 3, 2025 she will not seek re-election at the 2026 Annual Meeting.","Puma has served on the Board since 2021 and currently sits on the Talent Committee.","She will continue serving as a director and committee member until the 2026 Annual Meeting.","Her departure is not due to any disagreement with the Company, management, or Board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":3508347527.7428994,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125654,"accession_number":"0001104659-25-104442","cik":1821825,"company_name":"Organon & Co.","ticker":"OGN","form_type":"8-K/A","filed_at":"2025-10-30T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Organon sets Executive Chair Carrie S. Cox compensation at $100,000/month","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Carrie S. Cox appointed Executive Chair effective October 26, 2025.","Talent Committee approved base salary of $100,000 per month for interim period.","Amendment adds compensation details to prior 8-K filed October 27, 2025.","No other changes were made to the original Form 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3508347527.7428994,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125655,"accession_number":"0001104659-25-102324","cik":1821825,"company_name":"Organon & Co.","ticker":"OGN","form_type":"8-K","filed_at":"2025-10-27T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Organon CEO resigns after probe finds improper Nexplanon wholesaler sales; Morrissey named interim CEO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kevin Ali resigned as CEO and Board member; no severance or equity retirement benefits.","Audit Committee investigation found wholesalers asked to buy excess Nexplanon in 7 quarters; sales <1% of annual revenue but helped meet guidance.","Joseph Morrissey appointed Interim CEO; salary raised to $1M, bonus target 100%, LTI target $4M, one-time RSU grant of $1M.","Carrie Cox named Executive Chair; Robert Essner Lead Independent Director; Helene Gayle chairs Talent Committee.","No restatement of prior financials; 2024 internal control opinion withdrawn; Head of US Commercial & Government Affairs terminated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":3508347527.7428994,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142382,"accession_number":"0001104659-25-073929","cik":1821825,"company_name":"Organon & Co.","ticker":"OGN","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Organon Q2 revenue $1.594B, adj. EPS $1.00; raises FY revenue guidance to $6.275-6.375B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1.594B, down 1% YoY; GAAP net income $145M ($0.56 EPS); non-GAAP adj. EPS $1.00, down 11% YoY.","Adjusted EBITDA $522M (32.7% margin) vs $513M (31.9%) prior year; repaid $345M of long-term debt in Q2.","Women's Health revenue up 2% ex-FX; fertility business +15% ex-FX; Nexplanon flat ex-FX.","Biosimilars up 6% ex-FX (Hadlima growth); Established Brands down 4% ex-FX on Atozet LOE in Europe.","FY 2025 revenue guidance raised to $6.275-6.375B; adj. EBITDA margin guidance affirmed at 31-32%."],"consensus_eps_estimate":null,"consensus_eps_actual":0.89,"consensus_revenue_estimate":null,"consensus_revenue_actual":3107000000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.72,"calibrated_materiality_score":0.72,"market_cap_usd":3508347527.7428994,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160412,"accession_number":"0001104659-25-058900","cik":1821825,"company_name":"Organon & Co.","ticker":"OGN","form_type":"8-K","filed_at":"2025-06-12T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Organon stockholders approve amended 2021 Incentive Stock Plan adding 7.8M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amended plan increases share reserve by 7.8M shares; requires 95% of awards to have minimum 1-year vesting.","All 11 director nominees elected with >94% of votes cast (excluding broker non-votes) for each.","Say-on-pay advisory vote passed with 78.2% support (131.5M for, 35.1M against).","Stockholder proposal for director resignation guidelines rejected with 21.0% support (35.3M for, 131.5M against).","Ratification of PwC as auditor for FY2025 approved with 97.7% of votes cast."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3508347527.7428994,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160411,"accession_number":"0001104659-25-052994","cik":1821825,"company_name":"Organon & Co.","ticker":"OGN","form_type":"8-K","filed_at":"2025-05-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA designates Organon's HADLIMA as interchangeable biosimilar to Humira across all presentations","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA granted interchangeability for HADLIMA high- and low-concentration (40 mg/0.4 mL, 40 mg/0.8 mL) autoinjectors and high-concentration prefilled syringe.","HADLIMA is now interchangeable with all formulations of Humira, including low-concentration prefilled syringe and single-dose vial (granted June 2024).","Designation based on PK, efficacy, safety, and immunogenicity study of SB5 vs Humira in moderate to severe plaque psoriasis patients.","Interchangeability allows pharmacists to substitute HADLIMA for Humira without consulting prescriber, subject to state pharmacy laws.","Average patient out-of-pocket cost for Humira was more than four times that of HADLIMA, per Organon data."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3508347527.7428994,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160410,"accession_number":"0001104659-25-043023","cik":1821825,"company_name":"Organon & Co.","ticker":"OGN","form_type":"8-K","filed_at":"2025-05-01T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"Organon cuts dividend 93% to $0.08/yr; Q1 revenue down 7%, adj EPS $1.02","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $1.513B, -7% as-reported (-4% ex-FX); GAAP EPS $0.33, non-GAAP adj EPS $1.02.","Board declared quarterly dividend $0.02/share (vs prior $0.28), payable June 12 to holders of record May 12.","Women's Health +10% as-reported (+12% ex-FX) helped by Nexplanon; Biosimilars -17%; Established Brands -11%.","Vtama on track for $150M full-year revenue; affirms 2025 guidance, expects >$900M FCF before one-time costs.","Net income $87M, Adjusted EBITDA $484M (32% margin); company prioritizes deleveraging to net leverage <4.0x by year-end."],"consensus_eps_estimate":null,"consensus_eps_actual":0.33,"consensus_revenue_estimate":null,"consensus_revenue_actual":1513000000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3508347527.7428994,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160409,"accession_number":"0001104659-25-035173","cik":1821825,"company_name":"Organon & Co.","ticker":"OGN","form_type":"8-K","filed_at":"2025-04-15T23:59:59+00:00","items":["5.02","7.01"],"status":"ready","headline":"Organon appoints Ramona A. Sequeira to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointment effective July 1, 2025; Board expands to 12 directors.","Sequeira will serve on the Talent Committee of the Board.","She is President of Global Portfolio Division at Takeda with 30+ years pharma experience.","No related-party transactions or family relationships disclosed.","Standard non-employee director compensation applies; indemnification agreement to be entered."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":3508347527.7428994,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178674,"accession_number":"0001104659-25-012546","cik":1821825,"company_name":"Organon & Co.","ticker":"OGN","form_type":"8-K","filed_at":"2025-02-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Organon FY2024 revenue $6.4B (+2%); guides FY2025 revenue $6.125-6.325B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full year 2024 revenue $6,401M (+2% as-reported, +3% constant currency); diluted EPS $3.33; non-GAAP adjusted diluted EPS $4.11.","Q4 revenue $1,592M flat YoY; net income $109M vs $546M (down 80%) due to prior-year one-time gain; adjusted net income $235M (+4%).","FY2025 guidance: revenue $6,125M-$6,325M (incl. ~$200M FX headwind); Adjusted EBITDA margin 31-32% (FY2024: 30.6%).","Biosimilars Q4 revenue down 18% on tender timing and U.S. pricing pressure; Women's Health flat as Nexplanon +12% offset NuvaRing decline.","Established Brands +2% driven by Emgality (Lilly license) and Vtama (Dermavant acquisition closed Oct 2024), partly offset by Atozet LOE."],"consensus_eps_estimate":null,"consensus_eps_actual":3.33,"consensus_revenue_estimate":null,"consensus_revenue_actual":6403000000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3508347527.7428994,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178673,"accession_number":"0001104659-25-004711","cik":1821825,"company_name":"Organon & Co.","ticker":"OGN","form_type":"8-K","filed_at":"2025-01-21T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Organon CCO Susanne Fiedler departs effective Jan 15, senior advisor until April 30","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Susanne Fiedler ceased performing CCO functions effective January 15, 2025.","She will serve as a senior advisor until departure expected on or about April 30, 2025.","No successor has been named; the Company did not disclose the reason for departure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3508347527.7428994,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195339,"accession_number":"0001104659-24-130976","cik":1821825,"company_name":"Organon & Co.","ticker":"OGN","form_type":"8-K","filed_at":"2024-12-23T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Organon board reduces size to 11 after director McGarry's resignation","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Director Martha E. McGarry resigned from the board; resignation previously announced.","Board reduced its size to 11 members, eliminating the vacancy created by the resignation.","Change effective December 20, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":3508347527.7428994,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195338,"accession_number":"0001104659-24-126309","cik":1821825,"company_name":"Organon & Co.","ticker":"OGN","form_type":"8-K","filed_at":"2024-12-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Martha E. McGarry resigns from Organon Board effective December 4, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Martha E. McGarry notified the Board of her resignation effective December 4, 2024.","She also resigned as member of the Talent Committee.","Resignation not due to any disagreement with the Company's operations, policies, or practices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":3508347527.7428994,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195337,"accession_number":"0001104659-24-114101","cik":1821825,"company_name":"Organon & Co.","ticker":"OGN","form_type":"8-K","filed_at":"2024-11-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"FDA extends VTAMA sNDA review for atopic dermatitis to March 12, 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA extended target action date by 3 months to March 12, 2025; original date was December 12, 2024.","FDA requested final datasets and clinical study report from long-term extension study, deemed a major amendment.","No concerns raised regarding safety, efficacy, or approvability of VTAMA for atopic dermatitis.","Organon expects VTAMA full-year 2025 revenue of ~$125M; impact of ~75 bps headwind to Adjusted EBITDA margin.","Updated guidance provided as a supplement to prior Q3 2024 earnings call commentary."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3508347527.7428994,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195336,"accession_number":"0001104659-24-112866","cik":1821825,"company_name":"Organon & Co.","ticker":"OGN","form_type":"8-K","filed_at":"2024-10-31T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Organon Q3 revenue $1.582B (+4% YoY); narrows FY revenue guidance upward to $6.375-6.425B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP diluted EPS $1.38; non-GAAP adjusted diluted EPS $0.87 (includes $0.16 IPR&D charge).","Women's Health +5% as-reported; Nexplanon grew 11% ex-FX; fertility +14% ex-FX.","Biosimilars +16% as-reported; Hadlima launch drove uptake; Renflexis +4% ex-FX.","FY2024 revenue midpoint raised $50M to $6.375-6.425B; Adj. EBITDA margin guide revised to 30-31%.","Established Brands +2% as-reported; flat ex-FX growth expected for full year."],"consensus_eps_estimate":null,"consensus_eps_actual":2.92,"consensus_revenue_estimate":null,"consensus_revenue_actual":4811000000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3508347527.7428994,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211594,"accession_number":"0001104659-24-102053","cik":1821825,"company_name":"Organon & Co.","ticker":"OGN","form_type":"8-K","filed_at":"2024-09-23T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Organon acquires Dermavant Sciences for up to $1.2B; VTAMA drug portfolio","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Total consideration up to $1.2B: $175M upfront, $75M FDA milestone for atopic dermatitis, up to $950M commercial milestones.","Dermavant shareholders also earn tiered royalty payments based on VTAMA net sales.","Transaction expected to close Q4 2024, subject to HSR and other customary conditions.","VTAMA (tapinarof) is approved for plaque psoriasis; milestone targets atopic dermatitis indication."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3508347527.7428994,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211593,"accession_number":"0001104659-24-086103","cik":1821825,"company_name":"Organon & Co.","ticker":"OGN","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Organon Q2 2024 revenue flat at $1.607B; Adj. EPS $1.12, down 15% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1.607B flat YoY (up 2% constant currency); net income $195M vs $242M prior year.","Non-GAAP adjusted diluted EPS $1.12 (down 15% YoY); GAAP diluted EPS $0.75 (down 21%).","Women's Health +3%, Biosimilars +22% driven by Hadlima launch; Established Brands -1% ex-FX.","FY2024 revenue guidance narrowed to $6.25-6.45B; Adjusted EBITDA margin reaffirmed 31-33%."],"consensus_eps_estimate":null,"consensus_eps_actual":1.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":3229000000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3508347527.7428994,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230295,"accession_number":"0001104659-24-068876","cik":1821825,"company_name":"Organon & Co.","ticker":"OGN","form_type":"8-K","filed_at":"2024-06-06T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Organon shareholders elect all four Class III directors, approve say-on-pay and auditor ratification","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All four Class III director nominees elected: Kevin Ali, Martha E. McGarry, Philip Ozuah, Shalini Sharp each received >173M votes for.","Non-binding advisory vote on executive compensation approved with 149.7M for, 28.2M against, 1.0M abstain (approx. 84% of votes cast).","Ratification of PricewaterhouseCoopers as auditor for FY2024 approved with 219.8M for, 0.97M against, 0.77M abstain.","Turnout: 221.5M shares present (86% of outstanding 257.2M shares)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":3508347527.7428994,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230294,"accession_number":"0001104659-24-063008","cik":1821825,"company_name":"Organon & Co.","ticker":"OGN","form_type":"8-K","filed_at":"2024-05-17T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Organon issues $1B in senior notes, amends credit facilities to extend maturities and reduce rates","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $500M 6.750% senior secured notes due 2034 and $500M 7.875% unsecured notes due 2034.","Net proceeds to repay a portion of existing Dollar Term Facility borrowings.","Term loan maturity extended to May 2031; revolving facility extended to Dec 2027 and increased by $300M to $1.3B.","Interest rate on remaining $1.55B term loans reduced from Term SOFR+3.0% to Term SOFR+2.50%.","Revolving facility commitment fee reduced to 0.375%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3508347527.7428994,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230293,"accession_number":"0001104659-24-056017","cik":1821825,"company_name":"Organon & Co.","ticker":"OGN","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Organon Q1 2024 revenue up 5% to $1.62B; adjusted EPS $1.22, up 13% YoY; 2024 guidance reaffirmed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $1,622M (+5% as-reported, +7% constant currency); net income $201M (+14% YoY).","GAAP diluted EPS $0.78; non-GAAP adjusted diluted EPS $1.22 (+13% YoY); includes $0.05 IPR&D/milestone charge.","Women's Health revenue +11% on Nexplanon (+34% ex-FX); Biosimilars +46% led by Hadlima ($30M vs $5M).","Adjusted EBITDA $538M, margin 33.2%; full-year 2024 financial guidance ranges affirmed."],"consensus_eps_estimate":null,"consensus_eps_actual":0.78,"consensus_revenue_estimate":null,"consensus_revenue_actual":1622000000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3508347527.7428994,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248703,"accession_number":"0001104659-24-024358","cik":1821825,"company_name":"Organon & Co.","ticker":"OGN","form_type":"8-K","filed_at":"2024-02-15T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Organon Q4 revenue $1.60B (+8% YoY); FY23 EPS $3.99; FY24 guidance $6.2-6.5B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY23 revenue $6.3B (+1% as-reported, +3% constant currency).","FY23 diluted EPS $3.99, non-GAAP adjusted diluted EPS $4.14; Adj. EBITDA $1.9B (31% margin).","Q4 revenue $1.60B (+8% YoY); Q4 non-GAAP adj. diluted EPS $0.88 (+9%).","Biosimilars rev +49% (Hadlima >doubled); Women's Health +7% (Follistim +63% ex-FX).","FY2024 guidance: revenue $6.2-6.5B, Adj. EBITDA margin 31-33%."],"consensus_eps_estimate":null,"consensus_eps_actual":3.99,"consensus_revenue_estimate":null,"consensus_revenue_actual":6263000000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3508347527.7428994,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266196,"accession_number":"0001104659-23-123628","cik":1821825,"company_name":"Organon & Co.","ticker":"OGN","form_type":"8-K","filed_at":"2023-12-05T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Organon R&D Head Sandra Milligan to depart Jan 5; ceased role Dec 1","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Sandra Milligan, Head of Research and Development, will leave Organon on January 5, 2024.","She ceased performing her R&D functions effective December 1, 2023, and will serve as a senior advisor until her departure.","No replacement has been announced for the R&D leadership role."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3508347527.7428994,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266195,"accession_number":"0001104659-23-113589","cik":1821825,"company_name":"Organon & Co.","ticker":"OGN","form_type":"8-K","filed_at":"2023-11-02T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Organon Q3 revenue $1.52B, adj. EPS $0.87; narrows & lowers FY2023 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1,519M (-1% YoY); diluted EPS $0.23; non-GAAP adj. diluted EPS $0.87.","Women's Health -7% ex-FX; Biosimilars +10% ex-FX; Established Brands +3% ex-FX.","Board declares quarterly dividend $0.28 per share, unchanged.","FY2023 revenue guidance narrowed to $6.15-6.25B (prev. $6.15-6.35B); adj. EBITDA margin 30.5-31.5% (prev. 31-33%).","Adjusted EBITDA $447M, margin 29.4% vs 35.5% a year ago."],"consensus_eps_estimate":null,"consensus_eps_actual":1.86,"consensus_revenue_estimate":null,"consensus_revenue_actual":4665000000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3508347527.7428994,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283448,"accession_number":"0001104659-23-088621","cik":1821825,"company_name":"Organon & Co.","ticker":"OGN","form_type":"8-K","filed_at":"2023-08-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Organon Q2 2023 revenue $1.61B (+4% ex-FX); adj. EPS $1.31; FY guidance narrowed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP diluted EPS $0.95; non-GAAP adjusted diluted EPS $1.31 vs $1.25 prior year.","Women's Health revenue $438M (+10% ex-FX); Nexplanon up 12% ex-FX; fertility +17% ex-FX.","Biosimilars $135M (+15% ex-FX); Renflexis +20% ex-FX; Hadlima launched in US July 1.","Established Brands $995M (flat ex-FX); expects flat full-year revenue.","FY 2023 revenue guidance narrowed to $6.25-6.45B; adj. EBITDA margin 31.5%-33.0%."],"consensus_eps_estimate":null,"consensus_eps_actual":1.64,"consensus_revenue_estimate":null,"consensus_revenue_actual":3146000000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3508347527.7428994,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283447,"accession_number":"0001104659-23-079109","cik":1821825,"company_name":"Organon & Co.","ticker":"OGN","form_type":"8-K","filed_at":"2023-07-07T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Organon amends credit agreement to replace LIBOR with SOFR-based rates","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Amendment replaces LIBOR with Adjusted Term SOFR in senior secured credit agreement dated June 2, 2021.","No changes to principal amounts, interest rates, or maturity of existing loans.","Amendment effective June 30, 2023; no lender objection received."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":3508347527.7428994,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302917,"accession_number":"0001104659-23-069458","cik":1821825,"company_name":"Organon & Co.","ticker":"OGN","form_type":"8-K","filed_at":"2023-06-08T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Organon shareholders elect all Class II directors, approve say-on-pay, ratify auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All four Class II directors elected: Carrie S. Cox, Alan Ezekowitz, Helene Gayle, Deborah Leone.","Advisory vote on executive compensation approved: 170.5M for, 11.9M against.","Ratification of PwC as auditor for FY2023 passed: 215.3M for, 0.84M against.","Approximately 85% of outstanding shares (216.5M) represented at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":3508347527.7428994,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302916,"accession_number":"0001104659-23-055788","cik":1821825,"company_name":"Organon & Co.","ticker":"OGN","form_type":"8-K","filed_at":"2023-05-04T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Organon Q1 revenue $1.54B, net income $177M (-49%), adjusted EPS $1.08","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $1,538M, down 2% as-reported but up 3% ex-FX vs Q1 2022; all three franchises grew on constant currency basis.","GAAP diluted EPS $0.69 (down 49% YoY); non-GAAP adjusted diluted EPS $1.08 (down 35% YoY); includes $0.03 negative impact from IPR&D costs.","Adjusted EBITDA $518M (down 20% YoY); margin 33.7% vs 41.3% in Q1 2022.","Board declared $0.28 quarterly dividend; voluntary $250M debt repayment on term loan.","Full year 2023 financial guidance ranges affirmed."],"consensus_eps_estimate":null,"consensus_eps_actual":0.69,"consensus_revenue_estimate":null,"consensus_revenue_actual":1538000000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3508347527.7428994,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":322554,"accession_number":"0001104659-23-022617","cik":1821825,"company_name":"Organon & Co.","ticker":"OGN","form_type":"8-K","filed_at":"2023-02-16T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Organon reports FY 2022 revenue $6.2B (-2% as-reported); Q4 GAAP EPS $0.42, provides 2023 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY 2022 revenue $6.174B, down 2% as-reported, up 4% ex-FX; diluted GAAP EPS $3.59, non-GAAP adjusted $5.03.","Q4 2022 revenue $1.485B, down 7% as-reported, up 1% ex-FX; GAAP EPS $0.42, non-GAAP adjusted $0.81.","All three franchises grew on constant-currency basis in FY 2022; Nexplanon up 11% ex-FX, Biosimilars up 17% ex-FX.","Q4 included $36M inventory charges and $8M sales return reserve due to Heist facility market action.","2023 guidance: revenue $6.15B-$6.45B; Adjusted EBITDA margin 31%-33%; quarterly dividend $0.28/share declared."],"consensus_eps_estimate":null,"consensus_eps_actual":3.59,"consensus_revenue_estimate":null,"consensus_revenue_actual":6174000000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3508347527.7428994,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":340577,"accession_number":"0001104659-22-125576","cik":1821825,"company_name":"Organon & Co.","ticker":"OGN","form_type":"8-K","filed_at":"2022-12-09T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"Organon amends bylaws to adopt universal proxy card rules","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board approved Amended and Restated Bylaws effective December 6, 2022, to comply with Rule 14a-19.","New rules require shareholders to comply with universal proxy card requirements for director nominations.","Enhanced disclosure and procedural requirements for stockholder nominations and proposals.","Technical, modernizing and clarifying changes also made to the bylaws."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":3508347527.7428994,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":340576,"accession_number":"0001104659-22-114226","cik":1821825,"company_name":"Organon & Co.","ticker":"OGN","form_type":"8-K","filed_at":"2022-11-03T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Organon Q3 revenues $1.54B (-4% YoY); raises FY adjusted EBITDA margin guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $1,537M, down 4% YoY as-reported but up 3% ex-FX.","GAAP diluted EPS $0.89, non-GAAP adjusted diluted EPS $1.32.","Women's Health revenue grew 19% (23% ex-FX) on Nexplanon demand.","Full year 2022 revenue guidance narrowed to $6.1-$6.2B; adjusted EBITDA margin raised to 33.5%-34.5%.","Board declares quarterly dividend of $0.28 per share."],"consensus_eps_estimate":null,"consensus_eps_actual":3.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":4689000000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3508347527.7428994,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":357837,"accession_number":"0001104659-22-085887","cik":1821825,"company_name":"Organon & Co.","ticker":"OGN","form_type":"8-K","filed_at":"2022-08-04T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Organon Q2 revenues $1.585B (-1% as-reported, +5% ex-FX); adj EPS $1.25; FY guidance narrowed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenues $1,585M, down 1% as-reported but up 5% ex-FX vs Q2 2021; diluted EPS $0.92, adj diluted EPS $1.25 (both include -$0.30 IPR&D).","Adjusted EBITDA $512M (32.3% margin), inclusive of $97M acquired IPR&D and milestones.","Board declares quarterly dividend $0.28/share (unchanged).","Full-year 2022 revenue guidance narrowed to $6.1B-$6.3B; adj EBITDA margin 32%-34% reflecting FX and IPR&D.","Biosimilars revenue +42% ex-FX; Established Brands +4% ex-FX; Women's Health +1% ex-FX."],"consensus_eps_estimate":null,"consensus_eps_actual":2.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":3152000000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3508347527.7428994,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":357836,"accession_number":"0001104659-22-078988","cik":1821825,"company_name":"Organon & Co.","ticker":"OGN","form_type":"8-K","filed_at":"2022-07-12T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Organon General Counsel Deborah Telman resigns effective July 22, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["EVP, General Counsel and Corporate Secretary Deborah H. Telman resigned on July 7, 2022.","Resignation effective July 22, 2022; Telman left to pursue another opportunity.","No successor has been named as of the filing date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":3508347527.7428994,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":376481,"accession_number":"0001104659-22-069394","cik":1821825,"company_name":"Organon & Co.","ticker":"OGN","form_type":"8-K","filed_at":"2022-06-08T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Organon shareholders elect four Class I directors and approve say-on-pay at 2022 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Class I directors Robert Essner, Shelly Lazarus, Cynthia M. Patton, Grace Puma elected with >96% of votes cast.","Say-on-pay advisory vote passed with ~93% of votes cast in favor.","One-year frequency for future say-on-pay votes approved with ~98% of votes cast.","Ratification of PricewaterhouseCoopers as auditor for FY 2022 passed with ~99.5% of votes cast."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":3508347527.7428994,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":376480,"accession_number":"0001104659-22-056906","cik":1821825,"company_name":"Organon & Co.","ticker":"OGN","form_type":"8-K","filed_at":"2022-05-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Organon held Q1 2022 earnings call; financial results not provided in excerpt","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Company held conference call on May 5, 2022 to discuss Q1 2022 results.","Transcript furnished as Exhibit 99.1, but specific revenue, EPS, or guidance figures are absent from the supplied text.","Call referenced non-GAAP measures (Adjusted EBITDA, Adjusted Net Income, Adjusted Diluted EPS) and forward-looking statements.","Full-year 2022 guidance provided on non-GAAP basis due to unpredictability of certain GAAP items.","Earnings data from the quarter ended March 31, 2022 not available in this excerpt."],"consensus_eps_estimate":null,"consensus_eps_actual":1.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":1567000000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3508347527.7428994,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":376479,"accession_number":"0001104659-22-056278","cik":1821825,"company_name":"Organon & Co.","ticker":"OGN","form_type":"8-K","filed_at":"2022-05-05T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Organon Q1 revenue $1.567B (+8% ex-FX); adj. EPS $1.65; reaffirms FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1,567M, +4% as-reported / +8% ex-FX vs Q1 2021; Women's Health -5%, Biosimilars +22%, Established Brands +10%.","Net income from cont. ops $348M ($1.36 diluted EPS); adjusted net income $420M ($1.65 adj. diluted EPS).","Adjusted EBITDA $647M; gross margin 64.2% (adj. 66.5%); board declares $0.28 quarterly dividend.","Full year 2022 financial guidance reaffirmed; acquired rights to Marvelon/Mercilon and Xaciato license in certain markets."],"consensus_eps_estimate":null,"consensus_eps_actual":1.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":1567000000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3508347527.7428994,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":394824,"accession_number":"0001104659-22-024496","cik":1821825,"company_name":"Organon & Co.","ticker":"OGN","form_type":"8-K","filed_at":"2022-02-17T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Organon FY21 rev $6.3B, adj. EPS $6.54; provides FY22 guide rev $6.1-$6.4B, adj. EBITDA margin 34-36%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY21 revenue $6.3B (-3% as-reported vs 2020); GAAP diluted EPS $5.31; non-GAAP adj. diluted EPS $6.54.","Q4 revenue $1.604B (-1% YoY); adj. EBITDA margin 34.2% vs 42.2% in prior year.","Board declared $0.28 quarterly dividend payable March 17, 2022; record date Feb 28.","FY22 guidance: revenue $6.1-$6.4B; adj. EBITDA margin 34%-36%; interest ~$400M; tax rate 17.5%-19.5%.","Growth engines (Nexplanon, fertility, biosimilars) grew double digits; 4 business development deals since spin."],"consensus_eps_estimate":null,"consensus_eps_actual":5.31,"consensus_revenue_estimate":null,"consensus_revenue_actual":6304000000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3508347527.7428994,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":413485,"accession_number":"0001104659-21-137472","cik":1821825,"company_name":"Organon & Co.","ticker":"OGN","form_type":"8-K","filed_at":"2021-11-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Organon Q3 revenue $1.6B (-1% YoY); adj. EPS $1.67; FY guidance narrowed; dividend $0.28","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1,600M, down 1% as-reported and 3% ex-FX YoY; net income from continuing ops $323M ($1.27 diluted EPS).","Adjusted net income $424M ($1.67 diluted EPS); Adjusted EBITDA $636M (39.8% margin).","Women's Health revenue $381M (-10% as-reported); Biosimilars +41%; Established Brands -6%.","Board declares Q4 dividend $0.28/share, payable Dec 16, 2021, record Nov 22, 2021.","Affirms FY guidance, narrows revenue range to $6.2B-$6.3B and Adj. EBITDA margin to 36.5%-37.5%."],"consensus_eps_estimate":null,"consensus_eps_actual":4.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":4701000000.0,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3508347527.7428994,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":432033,"accession_number":"0001104659-21-103773","cik":1821825,"company_name":"Organon & Co.","ticker":"OGN","form_type":"8-K","filed_at":"2021-08-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Organon Q2 2021 revenue $1.6B, net income $431M; declares inaugural $0.28 quarterly dividend","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2021 revenue $1,595M (+5% as-reported; -1% ex-FX); Women's Health +19%, Biosimilars +43%, Established Brands -4%.","Net income from cont. ops. $431M ($1.70 diluted EPS); adjusted net income $437M ($1.72 adj. diluted EPS); adjusted EBITDA $627M.","Board declares quarterly dividend of $0.28/share, payable Sept 13, 2021 to holders of record Aug 23, 2021.","Full-year 2021 guidance affirmed: revenue $6.1B-$6.4B, adjusted EBITDA margin 36%-38%, interest ~$400M.","Cash and equivalents $730M, debt $9,348M, net debt $8,618M as of June 30, 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":3.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":3101000000.0,"consensus_period":"2021-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3508347527.7428994,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}